MorphoSys gets milestone from Novartis; acquires new technology


German company MorphoSys says it has received a milestone payment from Novartis in connection with the…

BiotechnologyLanthio PharmalanthipeptideMergers & AcquisitionsMorphoSysNovartisOphthalmicsResearch

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company


Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program


Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Proteon Thera gets new funding of $15 million, ahead of Novartis acquisition option


US privately-held biopharmaceutical firm Proteon Therapeutics, the subject of a takeover option by Swiss…

BiotechnologyFinancialMergers & AcquisitionsNovartisPharmaceuticalProteon TherapeuticsResearch

Silence Thera receives takeover approach from unnamed drug firm


UK-based drug developer Silence Therapeutics (AIM: SLN) saw its share price skyrocket 76% to 12.75 pence…

AstraZenecaBiotechnologyDainippon Sumitomo PharmaMergers & AcquisitionsNovartisPharmaceuticalSilence Therapeutics

A New lease of life for Big Pharma, by David Stevenson, writing for MoneyWeek


Few people – or businesses – were buoyed up by last week’s UK Pre-Budget Report (PBR).…

Abbott LaboratoriesBiotechnologyFinancialGeneralGenericsGlaxoSmithKlineGSKLicensingMarkets & MarketingMerck KGaAMergers & AcquisitionsNovartisparoxetinePatentsPaxilPfizerPharmaceuticalPneumococcal 7-valent ConjugatePoliticsPrevnarPricingRegulationRofecoxibSolvayVioxxWyeth

Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid


US stem-cell specialist Athersys’ shares rocketed almost 200% to $2.96 after it revealed yesterday…

AnidulafunginAntibiotics and Infectious diseasesBiotechnologyEraxisGastro-intestinalsGlaxoSmithKlineGSKHumulin 70-30Humulin NHumulin RInsulinLicensingMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalRoche

Back to top